138 related articles for article (PubMed ID: 37799222)
21. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
22. Malignant hyperthermia.
Kim DC
Korean J Anesthesiol; 2012 Nov; 63(5):391-401. PubMed ID: 23198031
[TBL] [Abstract][Full Text] [Related]
23. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study.
Klingler W; Heiderich S; Girard T; Gravino E; Heffron JJ; Johannsen S; Jurkat-Rott K; Rüffert H; Schuster F; Snoeck M; Sorrentino V; Tegazzin V; Lehmann-Horn F
Orphanet J Rare Dis; 2014 Jan; 9():8. PubMed ID: 24433488
[TBL] [Abstract][Full Text] [Related]
24. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC
Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312
[TBL] [Abstract][Full Text] [Related]
26. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
[TBL] [Abstract][Full Text] [Related]
27. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA
Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824
[TBL] [Abstract][Full Text] [Related]
28. Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.
Ibarra Moreno CA; Kraeva N; Zvaritch E; Jungbluth H; Voermans NC; Riazi S
Anesth Analg; 2023 Mar; 136(3):569-577. PubMed ID: 36201369
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of suspected malignant hyperthermia events during anesthesia.
Schuster F; Johannsen S; Schneiderbanger D; Roewer N
BMC Anesthesiol; 2013 Sep; 13(1):24. PubMed ID: 24053352
[TBL] [Abstract][Full Text] [Related]
30. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
31. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J
J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940
[TBL] [Abstract][Full Text] [Related]
32. Muscular body build and male sex are independently associated with malignant hyperthermia susceptibility.
Butala B; Brandom B
Can J Anaesth; 2017 Apr; 64(4):396-401. PubMed ID: 28063098
[TBL] [Abstract][Full Text] [Related]
33. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes.
Sei Y; Brandom BW; Bina S; Hosoi E; Gallagher KL; Wyre HW; Pudimat PA; Holman SJ; Venzon DJ; Daly JW; Muldoon S
Anesthesiology; 2002 Nov; 97(5):1052-8. PubMed ID: 12411786
[TBL] [Abstract][Full Text] [Related]
34. Malignant hyperthermia, environmental heat stress, and intracellular calcium dysregulation in a mouse model expressing the p.G2435R variant of RYR1.
Lopez JR; Kaura V; Diggle CP; Hopkins PM; Allen PD
Br J Anaesth; 2018 Oct; 121(4):953-961. PubMed ID: 30236258
[TBL] [Abstract][Full Text] [Related]
35. Malignant hyperthermia in maxillofacial surgery: Literature review supported by case presentation.
Aires CCG; de Souza RRL; Amorim JA; Santos FG; Diniz DA; Carneiro SCAS; Vasconcellos RJH
Spec Care Dentist; 2023 Jan; 43(1):99-108. PubMed ID: 35667046
[TBL] [Abstract][Full Text] [Related]
36. Ritanserin attenuates the in vitro effects of the 5-HT2 receptor agonist DOI on skeletal muscles from malignant hyperthermia-susceptible patients.
Wappler F; Scholz J; Oppermann S; von Richthofen V; Steinfath M; Schulte am Esch J
J Clin Anesth; 1997 Jun; 9(4):306-11. PubMed ID: 9195354
[TBL] [Abstract][Full Text] [Related]
37. Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.
Wappler F; Roewer N; Köchling A; Scholz J; Löscher W; Steinfath M
Anesthesiology; 1996 Jun; 84(6):1280-7. PubMed ID: 8669667
[TBL] [Abstract][Full Text] [Related]
38. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
Rueffert H; Olthoff D; Deutrich C; Froster UG
Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
[TBL] [Abstract][Full Text] [Related]
39. Attenuation of serotonin-induced contractures in skeletal muscle from malignant hyperthermia-susceptible patients with dantrolene.
Wappler F; Scholz J; von Richthofen V; Fiege M; Köchling A; Lambrecht W; Schulte am Esch J
Acta Anaesthesiol Scand; 1997 Nov; 41(10):1312-8. PubMed ID: 9422298
[TBL] [Abstract][Full Text] [Related]
40. Masseter muscle rigidity and the role of DNA analysis to confirm malignant hyperthermia susceptibility.
Hudig K; Pollock N; Bulger T; Machon RG; Woodhead A; Schiemann AH; Stowell KM
Anaesth Intensive Care; 2019 Jan; 47(1):60-68. PubMed ID: 30864471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
